Knight Therapeutics (TSE:GUD) achieved record-breaking financial results for the first half of 2026, prompting the company to raise its full-year guidance due to robust product growth, successful recent launches, and favorable foreign exchange tailwinds.
Record-Breaking Financial Performance
During the company’s second-quarter earnings call, President and CEO Samira Sakhia announced that Knight generated CAD 293 million in revenue, CAD 52 million in adjusted EBITDA, and CAD 70 million in operating cash flow during the first six months of 2026. The promoted portfolio served as a primary engine for this growth, contributing nearly CAD 200 million—a 36% increase on a constant-currency basis.
CFO Arvind Utchanah detailed the Q2 performance, noting quarterly revenue of CAD 144 million, representing a 34% increase year-over-year. Even when accounting for currency fluctuations, revenue grew by 22%, bolstered by new product launches and the integration of mature products from the Paladin and Sumitomo transactions.
Explosive Growth in Launch Pipeline
Knight’s launch-pipeline portfolio has become a significant revenue driver, generating CAD 18 million in the second quarter—a staggering 297% increase on a constant-currency basis. This performance underscores the impact of 17 product launches executed over the past 30 months. According to IQVIA data, sales of these launch-pipeline products in Canada surged by 189% compared to the same period last year.
The company’s strategic promoted products saw revenues reach CAD 76 million. When excluding AmBisome sales to the Brazilian Ministry of Health, the portfolio grew 16% on a constant-currency basis, driven by key assets including CRYSVITA, Lenvima, AKYNZEO, and INVOKANA. Meanwhile, the mature portfolio contributed CAD 48 million, a 32% increase, largely reflecting the recent strategic acquisitions.
Profitability and Operational Expansion
Adjusted gross margin improved to 49% of revenue, up from 46% in the prior-year period. While operating expenses (excluding amortization) rose 25% to CAD 47 million, management emphasized that this investment was necessary to support a growing infrastructure and a busier launch schedule. Adjusted EBITDA saw a significant jump of 58% to CAD 24 million, with adjusted EBITDA per share climbing 61% to CAD 0.25. The company did record a CAD 12 million net loss on financial assets, which Utchanah attributed to mark-to-market revaluations of equity and strategic fund investments.
Strategic Pipeline and Regulatory Updates
Knight has maintained a busy schedule, completing six launches in Canada and 11 in Latin America recently. Canadian additions include IMVEXXY, BIJUVA, Jornay PM, Xcopri, MYFEMBREE, and ORGOVYX. Latin American markets saw the introduction of MINJUVI, Pemazyre, TAVALISSE, and AKYNZEO across various territories.
Looking ahead to the second half of the year, Knight expects to roll out TAVALISSE in Brazil, WYNZORA in Canada, and additional branded generics across Latin America. Regarding regulatory hurdles, the company received a Notice of Non-Compliance from Health Canada for CREXONT. Sakhia confirmed that the company is collaborating with its partner to address the notice, noting that while the drug is already approved in the U.S. and nearing approval in Europe, it remains premature to determine if further clinical trials will be required.
Upgraded 2026 Outlook
Reflecting confidence in its performance, Knight raised its 2026 revenue guidance to a range of CAD 540 million to CAD 560 million, signaling at least 20% growth over 2025. Adjusted EBITDA is projected to reach at least 15% of revenue. Sakhia attributed the improved outlook to strong product performance and favorable currency impacts in Latin America, which added roughly CAD 10 million to first-half revenue.
Moving forward, the company plans to remain disciplined with capital deployment, focusing on product acquisitions and in-licensing while keeping share repurchases as a potential tool. Management expects EBITDA margins to continue expanding as newer products gain traction and operational costs stabilize.